Citigroup’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-200
Closed -$11K 7508
2020
Q1
$11K Sell
200
-380
-66% -$25.4K ﹤0.01% 6994
2019
Q4
$47K Sell
580
-156
-21% -$11K ﹤0.01% 6345
2019
Q3
$42K Sell
736
-116
-14% -$8.69K ﹤0.01% 6227
2019
Q2
$102K Buy
852
+504
+145% +$84.5K ﹤0.01% 5856
2019
Q1
$64K Buy
348
+336
+2,800% +$60.1K ﹤0.01% 6128
2018
Q4
$2K Sell
12
-276
-96% -$60.2K ﹤0.01% 7488
2018
Q3
$92K Buy
288
+160
+125% +$56.8K ﹤0.01% 5983
2018
Q2
$51K Buy
+128
New +$55.9K ﹤0.01% 6267

Other funds holding ABEO

Citigroup's ABEO Position: Q2 2026 in Review

Citigroup increased its Abeona Therapeutics (ABEO) stake by 4.9% in Q2 2026, buying an estimated $142K and bringing the position to 548,300 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Citigroup first reported a position in ABEO in Q2 2015 and has held it in 37 quarters since. The position peaked at $3.9M in Q3 2024. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Citigroup held 548,300 shares of Abeona Therapeutics worth $3.39M as of Q2 2026.
  • Citigroup bought 25,855 Abeona Therapeutics shares in Q2 2026, an estimated $142K.
  • Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2487 holding.
  • Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 37 quarters since.
  • Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.